New Concern: Drug-Drug Eluting Stent Interaction (DDESI) between Drugs Prescribed and Drug Eluting Stents (DESs) after Percutaneous Coronary Intervention (PCI) in Coronary Artery Disease (CAD) Patients: A Multicenter Cross-Sectional Observational Study

Abstract

Objective: This study was aimed to evaluate the interactions between commonly used drug eluting stents (DES) and prescribed medications in coronary artery disease (CAD) patients those underwent percutaneous coronary intervention (PCI). Study Design: Retro-prospective, Multicenter, Cross-sectional, Observational study. Methodology: A total of 127 CAD patients those successfully underwent PCI with different DES were enrolled in this study. The study population were divided into 3 groups; i) Patients stented with Sirolimus DES (n=52), ii) Everolimus DES (n=46) and iii) Zotarolimus DES (n=29) respectively, the patients case report and drug chart were reviewed periodically up to one-year regular follow-up period and retro-prospectively analysed. Results were statistically analysed using Graph Pad Prism software version 7.01 to determine the statistical difference between each study group. P<0.05 was considered as significant. Baseline clinical characteristics, angiographic and procedural characteristics, commonly prescribed medications and the new medical terminology Drug-Drug Eluting Stent Interaction abbreviated as DDESI were compared. Results: Out of 127 total populations, patients stented with Sirolimus DES reported less (0.85%) DDESI compared to Everolimus DES (2.54%) and Zotarolimus DES (1.69%) DDESI. Drugs such as aspirin, atorvastatin and clopidogrel were found to be three most commonly prescribed drugs to maximize benefits and minimize the complications in CAD patients those underwent PCI with different DES. Conclusion: According to the available patients data and results obtained it is concluded that Sirolimus DES was found to be more suitable and safe when compared to Everolimus DES and Zotarolimus DES after the one year regular follow-up period in CAD patients post PCI.